ENSC - Ensysce Biosciences Inc logo

Ensysce Biosciences Inc

ENSC

Ensysce Biosciences develops prescription drugs aimed at severe pain relief with a focus on opioid misuse prevention. Its main products include PF614, an abuse-resistant oxycodone prodrug, and other formulations for pain and opioid use disorder.

⚕️ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago →$0today

Score Overview

1 Year
Score
Net Growth-24.06%
Net TrendShrank
Net Income Consistency—
Rev Growth-11.17%
Rev TrendShrank
Revenue Consistency—
5 Years
Score4.9
Net Growth56.69%
Net Trend60%
Net Income Consistency—
Rev Growth27.46%
Rev Trend20%
Revenue Consistency—
All Time
Score—
Net Growth-5x
Net Trend50%
Net Income Consistency
Rev Growth—
Rev Trend38%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Ensysce Biosciences Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. ENSC does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 0.47—
1 Year2025-10-23
$ 2.11-77.70%
5 Years2021-10-22
$ 8.03K-99.99%
All Time2018-02-26
$ 34.74K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 4M-$ 12M$ 676.7K
2025$ 5M-$ 10M$ 4M
2024$ 5M-$ 7M$ 3M
2023$ 2M-$ 10M$ 1M
2022$ 2M-$ 24M$ 3M
2021$ 3M-$ 29M$ 12M
2020$ 3M$ 194.21K
2019$ 1M$ 1M$ 1M
IPO2018$ 0.00$ 2M$ 1M
ENSC - Ensysce Biosciences Inc logo

Ensysce Biosciences Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 3M to $ 5M. Revenue increased in 1 of those 5 years; net income in 3.

Ensysce Biosciences Inc currently holds a 5-year HDB Score of 4.9 out of 10. How the HDB Score is calculated.

Membership

Explore ENSC with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies